MONTHLY INTRAVITREAL INFLIXIMAB IN BEHcET'S DISEASE ACTIVE POSTERIOR UVEITIS A Long-Term Safety Study

Purpose: To study the safety of extended monthly intravitreal infliximab injections in patients with active posterior uveitis in Behcet's disease. Methods: This is a prospective, interventional, noncomparative, open-label, pilot study of 9 monthly intravitreal infliximab injections (1 mg/0.05 mL) for 22 eyes of 16 patients with active posterior uveitis in Behcet's disease. Control of inflammation and visual outcomes were assessed, and ocular complications were monitored during the study period. Results: Successful treatment was achieved in 7 eyes (35%), and failure was encountered in 13 eyes (65%). Only seven eyes of six patients (35%) had completed the study and achieved complete resolution of inflammation with improved best-corrected visual acuity and no complications. Failure was either because of inability to control the inflammation in nine eyes (45%) or development of exacerbation of inflammation in four eyes (20%). Four eyes developed severe immunological reaction from the drug after first (n = 1), second (n = 2), and third (n = 1) injections and had to discontinue the injections. Kaplan-Meier survival analysis showed that the mean estimated time to failure was 3.3 +/- 0.2 months, and all failed eyes required revision of their systemic immunotherapy to control the ocular inflammation. Conclusion: Intravitreal infliximab for active posterior uveitis in Behcet's disease was associated with a high complication rate and failure to control inflammation in most eyes. It should not be considered a substitute to systemic therapy.

Automated summary

The study on the safety and efficacy of extended monthly intravitreal infliximab injections in patients with active posterior uveitis in Behcet's disease revealed that the treatment was associated with a high complication rate and failure to control inflammation in most eyes, indicating that it should not be considered a substitute to systemic therapy.